JPMorgan raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $31 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 report. JPMorgan likes the setup for Acadia, seeing the stock as well positioned for further upside with continued commercial an pipeline momentum.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
- Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
- ACADIA Pharmaceuticals Charts Growth Path After Record Year
- Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
- Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen